Dr. Stanford Peng has more than 16 years of clinical and basic biomedical research experience in multiple settings. Prior to joining AIS, he was chief medical officer and head of clinical development at Stemcentrx prior to its acquisition by AbbVie, providing strategic oversight of the company’s clinical and translational programs. Before that, he served as executive medical director and head of inflammation and translational medicine at Seattle Genetics where he developed and executed translational, oncology, and immunology strategies and programs for antibody-drug conjugates. Earlier in his career he directed translational research and autoimmune-related clinical trials as head of the Rheumatology Clinical Research Unit at the Benaroya Research Institute in Seattle, held senior positions at ARYx Therapeutics, and held several positions at Roche — most recently as the translational medical leader of the Inflammation Disease Biology Area.

Dr. Peng has previously held clinical positions as a member physician at Virginia Mason Medical Center in Seattle and as an assistant professor in the Division of Rheumatology at the Washington University School of Medicine in St. Louis, Missouri.

Dr. Peng received his M.D. from Yale University School of Medicine and a Ph.D. in biology from Yale University. He completed his residency in internal medicine at the Hospital of the University of Pennsylvania School of Medicine in Philadelphia, followed by a clinical and research fellowship in rheumatology at Brigham and Women’s Hospital in Boston.